 ATLANTA--BUSINESS WIRE--- VIRI fibromyalgia--Virios Therapeutics, Inc. Nasdaq: VIRI, a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic pain and fatigue related diseases, announced today that all 41 sites involved in its ongoing 460 patient Phase 2b fibromyalgia FM trial are now fully activated and enrolling patients. This trial builds on the encouraging results from the Companys previously completed IMC-1 phase 2a FM clinical study. The 143-patient Phase 2 